REDWOOD CITY, Calif.,
Aug. 28, 2019 /PRNewswire/ -- Nevro
Corp. (NYSE: NVRO), a global medical device company that is
providing innovative, evidence-based solutions for the treatment of
chronic pain conditions, today announced that it has completed
patient enrollment in its prospective, multicenter Randomized
Controlled Trial (RCT) for the treatment of chronic pain for
patients who suffer from Painful Diabetic Neuropathy (PDN).
"This is an important step in the evaluation of Nevro's Senza
HF10 therapy for this very large and often undertreated patient
population," said D. Keith Grossman,
Nevro's Chairman, CEO and President. "Diabetes affects nearly
one in ten adults in the United
States and can damage peripheral nerves, resulting in severe
pain and numbness in the hands and feet. According to
published literature, there are approximately 4 million diabetic
patients suffering from painful diabetic neuropathy in the U.S.
alone. The SENZA-PDN study compares HF10 therapy plus
Conventional Medical Management (CMM) to CMM alone in 216 patients
at 18 centers in the United
States. The primary endpoint of the study is the difference
in proportion of treatment responders at 3-month follow-up and the
study will collect outcomes out to 24 months. This RCT is designed
to provide safety and efficacy data, which will be used to support
customer adoption and efforts to ensure adequate payor coverage of
this procedure. We thank Dr. Erika
Petersen, Director of Functional and Restorative
Neurosurgery at UAMS, for serving as the lead Principal
Investigator for this study."
About Nevro Corp.
Headquartered in Redwood City,
California, Nevro is a global medical device company focused
on providing innovative products that improve the quality of life
of patients suffering from debilitating chronic pain. Nevro has
developed and commercialized the Senza spinal cord stimulation
(SCS) system, an evidence-based, non-pharmacologic neuromodulation
platform for the treatment of chronic pain. The Senza® System and
Senza II™ System are the only SCS systems that deliver Nevro's
proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the
Nevro logo are trademarks of Nevro Corp.
Investor Relations:
Juliet
Cunningham
Vice President, Investor Relations
650-433-3247
ir@nevro.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/nevro-announces-completion-of-patient-enrollment-in-largest-multicenter-randomized-controlled-trial-of-high-frequency-spinal-cord-stimulation-for-painful-diabetic-neuropathy-300908153.html
SOURCE Nevro Corp.